Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · IEX Real-Time Price · USD
247.61
+4.29 (1.76%)
At close: Jul 2, 2024, 4:00 PM
248.00
+0.39 (0.16%)
After-hours: Jul 2, 2024, 6:21 PM EDT
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $2.00B in the twelve months ending March 31, 2024, with 75.20% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $494.33M with 54.82% year-over-year growth. In the year 2023, Alnylam Pharmaceuticals had annual revenue of $1.83B with 76.23% growth.
Revenue (ttm)
$2.00B
Revenue Growth
+75.20%
P/S Ratio
15.63
Revenue / Employee
$953,969
Employees
2,100
Market Cap
31.32B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
Dec 31, 2019 | 219.75M | 144.84M | 193.36% |
Dec 31, 2018 | 74.91M | -15.00M | -16.69% |
Dec 31, 2017 | 89.91M | 42.75M | 90.66% |
Dec 31, 2016 | 47.16M | 6.06M | 14.75% |
Dec 31, 2015 | 41.10M | -9.46M | -18.72% |
Dec 31, 2014 | 50.56M | 3.39M | 7.20% |
Dec 31, 2013 | 47.17M | -19.56M | -29.31% |
Dec 31, 2012 | 66.73M | -16.03M | -19.37% |
Dec 31, 2011 | 82.76M | -17.28M | -17.28% |
Dec 31, 2010 | 100.04M | -492.00K | -0.49% |
Dec 31, 2009 | 100.53M | 4.37M | 4.54% |
Dec 31, 2008 | 96.16M | 45.27M | 88.94% |
Dec 31, 2007 | 50.90M | 23.97M | 89.00% |
Dec 31, 2006 | 26.93M | 21.21M | 371.13% |
Dec 31, 2005 | 5.72M | 1.44M | 33.61% |
Dec 31, 2004 | 4.28M | 4.10M | 2,330.68% |
Dec 31, 2003 | 176.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Centene | 155.52B |
GE HealthCare Technologies | 19.50B |
IQVIA Holdings | 15.07B |
Biogen | 9.66B |
ICON PLC | 8.23B |
Agilent Technologies | 6.59B |
ResMed | 4.58B |
Mettler-Toledo International | 3.79B |
ALNY News
- 4 days ago - What's Next For Alnylam Stock After A 60% Rise In A Week? - Forbes
- 8 days ago - Alnylam Stock Soars on Strong Results in Heart Drug Study - Investopedia
- 8 days ago - Alnylam Pharmaceuticals reports promising heart disease trial results - Invezz
- 8 days ago - Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds - Forbes
- 8 days ago - Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge - Benzinga
- 8 days ago - Alnylam's stock surges as heart drug vies with a Pfizer blockbuster - Market Watch
- 8 days ago - Alnylam Stock Soars After Positive Results From Heart Disease Study - Barrons
- 8 days ago - Alnylam's heart disease drug meets main goal in late-stage study - Reuters